Paul-Moreau Bossous, MD
Nephrology · Mission, TXNPI 1487975439
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AstraZeneca at 28.4% of the total.
Across 103 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$647
- Fresenius USA Marketing, Inc.$495
- Bayer$368
- Vifor Pharma, Inc.$173
- Calliditas Therapeutics US Inc.$146
- Aurinia Pharma U.S., Inc.$108
- plus $340 from 9 others
What the payments were for
- Food & beverage$2,19496%
- Education$814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $647 |
| Fresenius USA Marketing, Inc. | 23 | $495 |
| Bayer | 22 | $368 |
| Vifor Pharma, Inc. | 9 | $173 |
| Calliditas Therapeutics US Inc. | 7 | $146 |
| Aurinia Pharma U.S., Inc. | 3 | $108 |
| E.r. Squibb & Sons, L.L.C. | 1 | $94 |
| Boehringer Ingelheim | 2 | $56 |
| Travere Therapeutics, Inc. | 3 | $53 |
| GSK | 2 | $33 |
| Akebia Therapeutics Inc | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Amgen | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$2,275 in reported general payments places this provider in the 55th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 1,139 | $1,176,496 |
| LokelmaSodium Zirconium Cyclosilicate | 283 | $461,431 |
| KerendiaFinerenone | 260 | $315,786 |
| TarpeyoBudesonide | 18 | $297,966 |
| VelphoroSucroferric Oxyhydroxide | 110 | $248,838 |
| VeltassaPatiromer Calcium Sorbitex | 89 | $158,801 |
| JardianceEmpagliflozin | 115 | $128,579 |
| JanuviaSitagliptin Phosphate | 132 | $97,263 |
| AuryxiaFerric Citrate | 13 | $32,541 |
| Sevelamer Carbonate | 122 | $20,739 |
| EntrestoSacubitril/Valsartan | 30 | $18,861 |
| VascepaIcosapent Ethyl | 40 | $14,532 |
| RybelsusSemaglutide | 13 | $13,557 |
| DapagliflozinDapagliflozin Propanediol | 19 | $9,495 |
| EdarbiAzilsartan Medoxomil | 14 | $7,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $647 | $1,637,9261,422 claims |
| BayerKerendia | $368 | $315,786260 claims |
| Calliditas Therapeutics US Inc.Tarpeyo | $146 | $297,96618 claims |
| Fresenius USA Marketing, Inc.Velphoro | $495 | $248,838110 claims |
| Boehringer IngelheimJardiance | $56 | $128,579115 claims |
| Akebia Therapeutics IncAuryxia | $25 | $32,54113 claims |
| Novo NordiskRybelsus | $24 | $13,55713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Mission
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.